000132222 001__ 132222
000132222 005__ 20241125101143.0
000132222 0247_ $$2doi$$a10.1016/j.jhepr.2023.100840
000132222 0248_ $$2sideral$$a137533
000132222 037__ $$aART-2023-137533
000132222 041__ $$aeng
000132222 100__ $$aPuchades, Lorena
000132222 245__ $$aWaiting time dictates impact of frailty: A Spanish multicenter prospective study
000132222 260__ $$c2023
000132222 5060_ $$aAccess copy available to the general public$$fUnrestricted
000132222 5203_ $$aBackground & aims: Frailty is prevalent in liver transplant (LT) candidates. It is considered an independent predictor of adverse outcomes pre- and post-transplant according to data obtained in the United States. We aimed to externally validate the liver frailty index (LFI) in a multicenter cohort of LT candidates.

Methods: Outpatients with cirrhosis were prospectively recruited from five Spanish centers (2018-2020). Patients were defined as "frail" by an optimal cut-off of LFI ≥4.5. Patients were followed for at least 6 months to study associations of pre-LT frailty with pre- and post-transplant mortality, length of hospital and intensive care unit (ICU) stays, risk of early (<30 days) and late (30-90 days) post-transplant complications, retransplantation and cardiovascular events.

Results: Of 212 patients included, 45 patients (21%) were frail pre-LT, and the median LFI was 3.9 (IQR 3.5-4.4). After a median waiting time of 78 days, 2% died or were delisted for clinical worsening. The LFI at baseline was not predictive of mortality/delisting in LT candidates in univariable or multivariable analyses after adjusting for age and MELD-Na score (hazard ratio 1.48; p = 0.586). In contrast, compared to non-frail patients, frail LT candidates had a significantly higher length of hospital stay (9 vs. 13 days; p = 0.001) and rate of early (<30 days) post-transplant complications (55% vs. 100%; p = 0.021).

Conclusions: In the context of a short LT waiting time, frailty does not impact pretransplant mortality and/or delisting. In contrast, LT frailty is predictive of higher post-transplant complication rates and length of hospital stay. Whether strategies aimed at pre- and/or re-habilitation are beneficial in settings with short waiting times needs to be confirmed in prospective studies.

Impact and implications: Literature is scarce on the actual impact of physical frailty on adverse outcomes in the liver transplant scenario outside North America. Evidence-based justification to extend the use of objective frailty tools in the decision-making processes in other liver transplant settings is needed. This study is the first to evaluate the predictive value of the liver frailty index in outpatients in the European liver transplant setting, showing that in a low MELD, high access system, frailty does not impact pretransplant mortality and/or delisting but is predictive of higher complication rates and longer post-transplant length of stay. In practical ways, physicians should consider physical frailty as a vital sign to be measured systematically and routinely during clinic visits; researchers are encouraged to initiate prospective studies to evaluate the benefit of applying strategies aimed at pre- and or re-habilitation in liver transplant settings with short waiting times.
000132222 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/CB06-04-0065$$9info:eu-repo/grantAgreement/ES/ISCIII/CM17-00006-LPR$$9info:eu-repo/grantAgreement/ES/ISCIII/INT20-00061-MB$$9info:eu-repo/grantAgreement/ES/ISCIII/PI19-01360-MB
000132222 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000132222 590__ $$a9.5$$b2023
000132222 592__ $$a3.409$$b2023
000132222 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b12 / 143 = 0.084$$c2023$$dQ1$$eT1
000132222 593__ $$aGastroenterology$$c2023$$dQ1
000132222 593__ $$aInternal Medicine$$c2023$$dQ1
000132222 593__ $$aImmunology and Allergy$$c2023$$dQ1
000132222 593__ $$aHepatology$$c2023$$dQ1
000132222 594__ $$a12.4$$b2023
000132222 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000132222 700__ $$aHerreras, Julia
000132222 700__ $$aIbañez, Ana
000132222 700__ $$aReyes, Érick
000132222 700__ $$aCrespo, Gonzalo
000132222 700__ $$aRodríguez-Perálvarez, Manuel
000132222 700__ $$aCortés, Luis$$uUniversidad de Zaragoza
000132222 700__ $$0(orcid)0000-0002-7119-2244$$aSerrano, Trinidad$$uUniversidad de Zaragoza
000132222 700__ $$aFernández-Yunquera, Ainhoa
000132222 700__ $$aMontalvá, Eva
000132222 700__ $$aBerenguer, Marina
000132222 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000132222 773__ $$g5, 11 (2023), 100840 [9 pp.]$$tJHEP Reports$$x2589-5559
000132222 8564_ $$s675841$$uhttps://zaguan.unizar.es/record/132222/files/texto_completo.pdf$$yVersión publicada
000132222 8564_ $$s1777467$$uhttps://zaguan.unizar.es/record/132222/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000132222 909CO $$ooai:zaguan.unizar.es:132222$$particulos$$pdriver
000132222 951__ $$a2024-11-22-12:03:12
000132222 980__ $$aARTICLE